Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: A systematic review and meta-analysis

Asia-Pacific Psychiatry

Volumn 6, Issue 3, 2014, Pages 241-251

  Yan, Tingting ^a   Wang, Lijuan ^b   Kuang, Weihong ^a   Xu, Jiajun ^a   Li, Suping ^c   Chen, Jie ^a   Yang, Yanchun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c HUBEI UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Antidepressant; BDNF; Meta analysis; Polymorphism; Response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ASIAN; CANCER REGRESSION; CAUCASIAN; CHINESE BIOMEDICAL DATABASE; CNKI DATABASE; DRUG EFFICACY; EMBASE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; WANFANG DATABASE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; MAJOR DEPRESSION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; TREATMENT OUTCOME;

EID: 84922127622     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/appy.12148     Document Type: Review

References (54)

1. Alexopoulos G.S., Glatt C.E., Hoptman M.J., etal. (2010) BDNF Val66Met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord. 125, 262-268.
2. American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 157, 1-45.
3. Baker W.L., White C.M., Cappelleri J.C., Kluger J., Coleman C.I. (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract. 63, 1426-1434.
4. Bauer M., Bschor T., Pfennig A., etal. (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 8, 67-104.
5. Castren E., Rantamaki T. (2010) The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 70, 289-297.
6. Cattaneo A., Gennarelli M., Uher R., etal. (2013) Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline "predictors" and longitudinal "targets". Neuropsychopharmacology. 38, 377-385.
7. Chi M.H., Chang H.H., Lee S.Y., etal. (2010) Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord. 126, 430-435.
8. Choi M.J., Kang R.H., Lim S.W., Oh K.S., Lee M.S. (2006) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 1118, 176-182.
9. Domschke K., Lawford B., Laje G., etal. (2010) Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 13, 93-101.
10. D'Sa C., Duman R.S. (2002) Antidepressants and neuroplasticity. Bipolar Disord. 4, 183-194.
11. Duval S., Tweedie R. (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 56, 455-463.
12. Egan M.F., Kojima M., Callicott J.H., etal. (2003) The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112, 257-269.
13. Fochtmann L.J., Gelenberg A.J. (2005) Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn. American Psychiatric Association, Washington, DC.
14. Gatt J.M., Nemeroff C.B., Dobson-Stone C., etal. (2009) Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry. 14, 681-695.
15. Gatt J.M., Nemeroff C.B., Schofield P.R., etal. (2010) Early life stress combined with serotonin 3a receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biol Psychiatry. 68, 818-824.
16. Groves J.O. (2007) Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 12, 1079-1088.
17. Hashimoto K., Shimizu E., Iyo M. (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. 45, 104-114.
18. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. (2003) Measuring inconsistency in meta-analyses. BMJ. 327, 557-560.
19. Hong C.J., Huo S.J., Yen F.C., Tung C.L., Pan G.M., Tsai S.J. (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology. 48, 186-189.
20. Hwang J.P., Tsai S.J., Hong C.J., Yang C.H., Lirng J.F., Yang Y.M. (2006) The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging. 27, 1834-1837.
21. Itoh K., Hashimoto K., Kumakiri C., Shimizu E., Iyo M. (2004) Association between brain-derived neurotrophic factor 196 g/a polymorphism and personality traits in healthy subjects. Am J Med Genet B Neuropsychiatr Genet. 124B, 61-63.
22. Kang R.H., Chang H.S., Wong M.L., etal. (2010) Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol. 24, 1755-1763.
23. Kato M., Serretti A. (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 15, 473-500.
24. Katsuki A., Yoshimura R., Kishi T., etal. (2012) Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr. 17, 155-163.
25. Kim H., Lim S.W., Kim S., etal. (2006) Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 296, 1609-1618.
26. Kocabas N.A., Antonijevic I., Faghel C., etal. (2011) Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol. 26, 1-10.
27. Lee Y., Lim S.W., Kim S.Y., etal. (2013) Association between the BDNF Val66Met polymorphism and chronicity of depression. Psychiatry Investig. 10, 56-61.
28. Licinio J., Dong C., Wong M.L. (2009) Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry. 66, 488-497.
29. Lin E., Chen P.S., Huang L.C., Hsu S.Y. (2008) Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders. Pharmgenomics Pers Med. 1, e1-e6.
30. Lin E., Hong C.J., Hwang J.P., etal. (2009) Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res. 12, 387-393.
31. Mrazek D.A., Lerman C. (2011) Facilitating clinical implementation of pharmacogenomics. JAMA. 306, 304-305.
32. Musil R., Zill P., Seemüller F., etal. (2012) No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci. 263, 405-412.
33. Pei Y., Smith A.K., Wang Y., etal. (2012) The brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism is associated with geriatric depression: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 159B, 560-566.
34. Perroud N., Aitchison K.J., Uher R., etal. (2009) Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology. 34, 2517-2528.
35. Racagni G., Popoli M. (2008) Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 10, 385-400.
36. Rajewska-Rager A., Skibinska M., Szczepankiewicz A., etal. (2008) Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression. Psychiatr Pol. 42, 915-923.
37. Schumacher J., Abou Jamra R., Becker T., etal. (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 58, 307-314.
38. Shi Y.Y., Yuan Y.G., Hou G., etal. (2010) Effect of brain-derived neurotrophic factor Val66Met polymorphism and environmental factors on antidepressant treatment. Chin J Behav Med Brain Sci. 19, 481-484.
39. Song X., Sun N., Liu S., etal. (2011) Association analysis between BDNF gene polymorphism and the efficacy of citalopram. National Medical Frontiers of China. 6, 20-22.
40. Su N., Zhang L., Fei F., etal. (2011) The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 1415, 119-126.
41. Taylor W.D., Züchner S., McQuoid D.R., Steffens D.C., Speer M.C., Krishnan K.R. (2007) Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. Am J Geriatr Psychiatry. 15, 850-857.
42. Taylor W.D., McQuoid D.R., Ashley-Koch A., etal. (2011) BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 11, 146-154.
43. Terracciano A., Martin B., Ansari D., etal. (2010) Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav. 9, 512-518.
44. Thompson S.G., Higgins J.P.T. (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med. 21, 1559-1573.
45. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 123B, 19-22.
46. Ventriglia M., Chiavetto L.B., Benussi L., etal. (2002) Association between the BDNF 196 a/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry. 7, 136-137.
47. Verhagen M., van der Meij A., van Deurzen P.A., etal. (2010) Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 15, 260-271.
48. Wilkie M.J., Smith D., Reid I.C., etal. (2007) A splice site polymorphism in the g-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics. 17, 207-215.
49. Wu T.W., Yang B., Cai S.R., Cui C.S. (2008) Brain-derived neurotrophic factor gene polymorphism (G196a) and paroxetine response in female depressive disorder. Prog Obstet Gynecol 17, 585-588.
50. Yoshida K., Higuchi H., Kamata M., etal. (2007) The G196a polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol. 21, 650-656.
51. Yoshimura R., Kishi T., Suzuki A., etal. (2011) The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry. 35, 1022-1025.
52. Zhang L., Fang Y., Zeng Z., etal. (2011) BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis. 26, 523-530.
53. Zou Y.F., Ye D.Q., Feng X.L., Su H., Pan F.M., Liao F.F. (2010a) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 20, 535-544.
54. Zou Y.F., Wang Y., Liu P., etal. (2010b) Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 61, 71-78.